

LUPUS REFERRAL FORM

Phone: 855.896.9254 Fax: 877.645.7514 10004 S. 152nd St, Suite A, Omaha NE 68138

Patient Information PLEASE FAX INSURANCE CARD (FRONT AND BACK)					Prescriber Information					
Last Name	First Name	DC	DB	Practice/Facility N	lame					
Address			Address							
City	State		ZIP	City		State	ZIP			
Phone SSN				Prescriber Name						
Allergies				Prescriber NPI						
Sex Male Female	Weight (kg)	He	eight (ft,in)	Nurse/Key Contact		Pho	Phone/Pager			
Insurance Plan	Pla	an ID #		Fax		Email	mail			
Diagnosis/Clinical Information										
ICD-10-CM: M32.10 Systemic lupus erythematosus M32.9 Systemic lupus prythematosus, unspecified Other:										
Patient previously treated for lupus: No Yes										
Previous therapies:										
Current therapies:										
Medication list:										
Pre-medications (to be takenminutes prior to infusion):										
Drug Strength		Directions			QTY F		Refill	Refill		
Site of care for patient:	Office Infusion	on center	Home health agency	,						
Prescription Informa	tion									
MEDICATION	STRENGTH		DIRECTIONS					QTY	REFILLS	
Benlysta (Initial Dosing) (belimumab)	120mg (5mL	vial)	Initial dosing: Infuse 10mg/kg IV over one hour every 2 weeks for first 3 doses					QS	0	
Current weight:kg	400mg (20m	ıL vial)	Total dose:mg							
Benlysta (Maintenance Dosing (belimumab)	(5mL)	vial)	laintenance dosing: Infuse 10mg/kg IV over one hour every 4 weeks					QS		
IV Administration Current weight:kg	400mg (20m	ıL vial)	Total dose:mg							
Benlysta (Maintenance Dosing) (belimumab)	imab) 200mg/mL PFS		Inject 200mg SC once weekly					28 day		
SC Administration Current weight:kg 200mg/mL Aut		autoinjector						supply		
Date needed:/ Medication delivery to (choose one): Prescriber Other:										
In order for a brand name pro	· ·	the prescrib	oer must handwrite "Brand N	lecessary" or "I	Brand Medically I	Necessary	," or yo	ur state-	specific	
required language to prohibit substitution: PRESCRIBER MUST MANUALLY SIGN - STAMP SIGNATURE, SIGNATURE BY OTHER PERSONNEL AND COMPUTER-GENERATED SIGNATURES WILL NOT BE ACCEPTED										
PRODUCT SUBSTITUTION PER	MITTED/Brand exchang	ge permitte	ed (Date) DISPE	NSE AS WRITT	EN/Do Not Subst	titute			(Date)	

I authorize Amber Pharmacy and its representatives to act as my agent in order to initiate and execute the insurance prior authorization process and, in doing so, to release clinical information via phone to the appropriate third party payer.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.